Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of proline and derivatives, specifically a pyrrolidine-based hydrazide. It is listed as an experimental drug in DrugBank (DB07366). The structure features a pyrrolidine ring substituted with a hydrazinocarbonyl group and an aminobutyl side chain, with the carboxylic acid moiety protected as a benzyl ester. There is no evidence of clinical approval or established therapeutic use. Its mechanism of action has not been definitively described in public databases, but related compounds have been investigated as metalloprotease inhibitors[1][5]. No information on primary indication, developer, or manufacturer is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[N'-(4-amino-butyl)-hydrazinocarbonyl]-pyrrolidine-1-carboxylic acid benzyl ester.